Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Mirum Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has approved […]
Mirum Pharmaceuticals Submits Supplemental New Drug Application for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals has announced that it has submitted a supplemental New Drug Application (sNDA) for […]
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of industry veteran William C. Fairey […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more